462093-61-4Relevant articles and documents
Novel compounds, their preparation and use
-
Page/Page column 32, (2010/02/11)
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be u
N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-opioid receptor agonists. Effects on μ-affinity of arylalkenyl chain modifications
Pinna, Gérard A.,Cignarella, Giorgio,Loriga, Giovanni,Murineddu, Gabriele,Mussinu, Jean-Mario,Ruiu, Stefania,Fadda, Paola,Fratta, Walter
, p. 1929 - 1937 (2007/10/03)
Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid μ-, δ- and κ-receptors were evaluated. Several compounds (1e,i,j-2d,e,f,g,j) exhibited a μ-affinity in the low nanomolar range with moderate or negligible affinity towards δ- and κ-receptors. The representative term N-9-(3,3-diphenylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine.